EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Connecting Gene Variation to Treatment Outcomes in Metastatic Castration-Resistant Prostate Adenocarcinoma: Insights into Second-Generation Androgen Receptor Axis-Targeted Therapies

Ana Vaz-Ferreira iD, Valéria Tavares iD, Inês Guerra de Melo, Patrícia Rafaela Rodrigues, Ana Afonso, Maria Joaquina Maurício, Rui Medeiros iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25189874 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Ana Vaz-Ferreira und 6 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Department, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Polymorphism, Single Nucleotide, Receptors, Androgen, Abiraterone Acetate. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Portuguese Institute of Oncology of Porto (IPO Porto), Fundação para Ciência e Tecnologia (FCT), Fundação para a Ciência e Tecnologia (FCT).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PC) is one of the most commonly diagnosed tumours among men. Second-generation androgen receptor axis-targeted (ARAT) agents, namely abiraterone acetate (AbA) and enzalutamide (ENZ), are currently used in the management of metastatic castration-resistant PC (mCRPC). However, the treatment is challenging due to the lack of prognostic biomarkers. Meanwhile, single-nucleotide polymorphisms (SNPs) have emerged as potential prognostic indicators of mCRPC. Thus, this study evaluated the impact of relevant SNPs on the treatment outcomes of 123 mCRPC patients enrolled in a hospital-based cohort study. The CYP17A1 rs2486758 C allele was associated with a 50% reduction in the risk of developing castration resistance (hazard ratio (HR) = 0.55; p = 0.003). Among patients without metastasis at tumour diagnosis and under AbA, a marginal association between YBX1 rs10493112 and progression-free survival was detected (log-rank test, p = 0.056). In the same subgroup, significant associations of HSD3B1 rs1047303 (CC/CA vs. AA; HR = 3.41; p = 0.025), YBX1 rs12030724 (AT vs. AA; HR = 3.54; p = 0.039) and YBX1 rs10493112 (log-rank test, p = 0.041; CC vs. AA/AC; HR = 3.22; p = 0.053) with overall survival were also observed, which were confirmed by multivariate Cox analyses. Although validation with larger cohorts is required, these findings suggest that SNPs could enhance the prognosis assessment of mCRPC patients, leading to a more personalised treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantPolymorphism, Single NucleotideReceptors, AndrogenAbiraterone AcetateHumansMaleAgedMiddle AgedPhenylthiohydantoinTreatment OutcomeNitrilesBenzamidesSteroid 17-alpha-HydroxylaseAged, 80 and overPrognosisY-Box-Binding Protein 1AdenocarcinomaNeoplasm MetastasisBiomarkers, Tumor

Stichwörter der Autor:innen

SNPsabiraterone acetatecastration resistanceenzalutamideprostatic neoplasmstreatment outcomes

Substanzen

Receptors, AndrogenAbiraterone AcetatePhenylthiohydantoinenzalutamideNitrilesBenzamidesSteroid 17-alpha-HydroxylaseCYP17A1 protein, humanY-Box-Binding Protein 1YBX1 protein, human

Autor:innen und Institutionen

  • Oncology Department, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal.
  • Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)/Pathology and Laboratory Medicine Department, Clinical Pathology SV/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Instit…
  • Faculty of Medicine of University of Porto (FMUP), 4200-072 Porto, Portugal.
  • ICBAS-Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, 4050-313 Porto, Portugal.
  • Faculty of Health Sciences, Fernando Pessoa University, 4200-150 Porto, Portugal.
  • Research Department, Portuguese League Against Cancer (NRNorte), 4200-172 Porto, Portugal.

ORCID-Profile: Ana Vaz-Ferreira, Valéria Tavares, Rui Medeiros

Förderung

  • Portuguese Institute of Oncology of Porto (IPO Porto)
  • Fundação para Ciência e Tecnologia (FCT)
  • Fundação para a Ciência e Tecnologia (FCT)

Zitieren

APA

Vaz-Ferreira, A., Tavares, V., de Melo, I. G., Rodrigues, P. R., Afonso, A., Maurício, M. J., & Medeiros, R. (2024). Connecting Gene Variation to Treatment Outcomes in Metastatic Castration-Resistant Prostate Adenocarcinoma: Insights into Second-Generation Androgen Receptor Axis-Targeted Therapies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25189874

Vancouver

Vaz-Ferreira A, Tavares V, de Melo IG, Rodrigues PR, Afonso A, Maurício MJ, et al. Connecting Gene Variation to Treatment Outcomes in Metastatic Castration-Resistant Prostate Adenocarcinoma: Insights into Second-Generation Androgen Receptor Axis-Targeted Therapies. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25189874

BibTeX
@article{VazFerreira2024,
  author = {Vaz-Ferreira, Ana and Tavares, Valéria and de Melo, Inês Guerra and Rodrigues, Patrícia Rafaela and Afonso, Ana and Maurício, Maria Joaquina and Medeiros, Rui},
  title = {Connecting Gene Variation to Treatment Outcomes in Metastatic Castration-Resistant Prostate Adenocarcinoma: Insights into Second-Generation Androgen Receptor Axis-Targeted Therapies},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25189874}
}
Kostenlos starten →